Evaxion Biotech AS Total Liabilities
Evaxion Biotech AS total liabilities. Based on the latest financial reports, Evaxion Biotech AS (EVAX) has total liabilities worth $9.85 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Evaxion Biotech AS liquidity resilience to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Evaxion Biotech AS (2017–2025)
Total liabilities of Evaxion Biotech AS from 2017 to 2025. This chart illustrates how Evaxion Biotech AS's total liabilities have evolved over time, based on quarterly financial data.
Evaxion Biotech AS Competitors by Total Liabilities
The table below lists competitors of Evaxion Biotech AS ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Galva Technologies Tbk PT
JK:GLVA
|
Indonesia | Rp559.80 Billion |
|
TOP Engineering Co. Ltd
KQ:065130
|
Korea | ₩200.30 Billion |
|
CPI Aerostructures Inc
NYSE:CVU
|
USA | $49.07 Million |
|
Sanatana Resources
V:STA
|
Canada | CA$1.12 Million |
|
Nexam Chemical Holding AB
ST:NEXAM
|
Sweden | Skr57.20 Million |
|
Baylin Technologies Inc
TO:BYL
|
Canada | CA$59.92 Million |
|
Romcarbon Sa B
RO:ROCE
|
Romania | RON152.62 Million |
|
Megachem (Thailand) Public Company Limited
BK:MGT
|
Thailand | ฿330.14 Million |
Liability Composition Analysis (2017–2025)
This chart breaks down Evaxion Biotech AS's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Evaxion Biotech AS total assets.
Liquidity & Leverage Metrics
Evaxion Biotech AS Total Liabilities Ratios Explained
Evaxion Biotech AS total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 5.06 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.03 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.51 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Evaxion Biotech AS's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Evaxion Biotech AS (2017–2025)
The table below shows the annual total liabilities of Evaxion Biotech AS from 2017 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $11.37 Million | -19.58% |
| 2024-12-31 | $14.14 Million | -19.76% |
| 2023-12-31 | $17.62 Million | +28.39% |
| 2022-12-31 | $13.72 Million | +77.61% |
| 2021-12-31 | $7.73 Million | +56.81% |
| 2020-12-31 | $4.93 Million | +186.12% |
| 2019-12-31 | $1.72 Million | -81.77% |
| 2018-12-31 | $9.44 Million | +2266.92% |
| 2017-12-31 | $399.00K | -- |
About Evaxion Biotech AS
Evaxion A/S, a clinical-stage biotech company, develops artificial intelligence-powered immunology vaccines. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of advanced melanoma; EVX-03, DNA-based cancer vaccine for the treatment of solid tumors; and EVX-04, a therapeutic cancer vaccine candidate, which is in phase 1 trial for acute myeloid le… Read more